There’s an Active Recall on Thyroid Medicine Nationwide

Live updates

1. 14d ago

   Vitruvias Therapeutics Recalls Over 3,600 Bottles of Superpotent Thyroid Tablets

   Vitruvias Therapeutics Inc. has issued a voluntary nationwide recall for more than 3,600 bottles of 30 mg Thyroid Tablets, USP. Lab testing indicated the medication is superpotent, meaning the pills may be too strong for patients. The FDA warned that these tablets can cause hyperthyroidism. Affected users must check for Lot No. 504950 to determine if their supply is part of the recall. Patients should contact their healthcare providers regarding potential health risks and next steps for replacement medication.

   Why it matters

   Thyroid medication requires precise dosing to maintain hormonal balance. Excessive potency can trigger hyperthyroidism, a condition where the thyroid is overactive. This recall targets a specific lot to prevent patient overdose.

   What is confirmed

   • Vitruvias Therapeutics Inc. issued a voluntary nationwide recall for Lot No. 504950 of 30 mg Thyroid Tablets, USP.
   • Lab testing showed the recalled pills may be too strong or superpotent.
   • The recall involves more than 3,600 bottles of the medication.
   • The FDA warned that these tablets may cause hyperthyroidism in patients.

   What to watch next

   • Reports of adverse patient reactions linked to Lot No. 504950
   • FDA updates on additional affected lots
   • Company statements regarding the cause of the potency error
   Sources used for this update (4)

   1. bigfrog104.com — Vitruvias Thyroid Pill Recall: What Potential Users in CNY Need to Know
   2. medicalxpress.com — Thyroid tablets recalled nationwide due to potential over-potency risk
   3. www.dermatologyadvisor.com — Thyroid Tablets Recalled Nationwide Due To Potential Over-Potency Risk
   4. www.rheumatologyadvisor.com — Thyroid Tablets Recalled Nationwide Due to Potential Over-Potency Risk
   confidence 100%
2. 20d ago

   FDA warns of superpotent thyroid medication in nationwide recall

   Vitruvias Therapeutics Inc. issued a voluntary nationwide recall for one lot of 30 mg Thyroid Tablets, USP, after testing revealed the medication could be "superpotent." The FDA issued an urgent alert warning that these tablets may cause hyperthyroidism in patients. The recall specifically affects Lot No. 504950. Patients using this medication should check their product lot numbers to determine if their supply is affected by the potency issue.

   Why it matters

   Thyroid medication regulates metabolism and heart rate. Superpotent doses can trigger hyperthyroidism, a condition where the thyroid is overactive. This recall ensures patients do not receive dosages higher than prescribed.

   What is confirmed

   • Vitruvias Therapeutics Inc. voluntarily recalled Lot No. 504950 of Thyroid Tablets, USP 30 mg.
   • The affected thyroid medication was distributed nationwide.
   • The FDA issued an urgent recall alert because the tablets could be "superpotent."
   • Testing indicates the superpotent tablets could lead to hyperthyroidism.

   What to watch next

   • FDA reports on the number of patients affected by the superpotent lot
   • Further recall notices for additional lots from Vitruvias Therapeutics Inc.
   Sources used for this update (7)

   1. NBC 5 Chicago — Thyroid tablets recalled because they could be ‘superpotent,' lead to hyperthyroidism
   2. USA Today — Thyroid medicine recalled. See affected product
   3. FOX 8 News — Thyroid tablets could be ‘superpotent,’ warns FDA in urgent recall alert
   4. WTHR — Thyroid medication recalled as product can be 'superpotent,' FDA says
   5. EatingWell — There’s an Active Recall on Thyroid Medicine Nationwide
   6. www.yahoo.com — FDA Announces Recall of Thyroid Medicine Due to Potential “Super Potency”
   7. www.yahoo.com — Thyroid medication recalled nationwide because tablets may be too potent
   confidence 100%